CTOs on the Move

Daily Cardinal Alumni Association

www.dailycardinal.net

 
Daily Cardinal Alumni Association is a Oak Park, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Access Health CT

Access Health CT is bringing the benefits of Health Care Reform to Connecticut. As the state`s official health insurance marketplace, we`re making it easier and more affordable for individuals, families, and small businesses to get quality health care coverage.

Spencer House

Spencer House is a South Beach, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Wellteq

Wellteq is creating the future of precision wellness through a digital wellbeing ecosystem taking users from point of prevention through to point of care. Delivered into the corporate health and insurance sector to drive user engagement through a personalised wellness journey. wellteq uses a range of data types from wearable devices, sensors, biomarkers and user-generated data that, in combination with machine learning and artificial intelligence enables individual-level insights into Stress, Fatigue, Sleep Quality, Cognitive Function and Activity levels. Behavioural science and content targeting use biometric and behavioural analytics to deliver personalised wellness insights and practical recommendations to build engagement, agency and more effective sustainable management of personal wellness. Programs are highly customisable and provide an experience packed with gamification, group projects, social interaction rewards and charity all to maximise healthy behavioural change. With customisation comes flexibility, which is paramount for businesses of all shapes and sizes around the world today.

Thomas Scientific

Thomas Scientific is a Swedesboro, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Scynexis

SCYNEXIS, Inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. Our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. We are developing our lead product candidate, SCY-078, a novel antifungal in Phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.